Pfizer – Page 6

Bristol Myers Squibb and Pfizer Unveil Promising Colorectal Cancer Treatments at ASCO GI 2025

9 months ago talkbio0Tagged 2025, Braftovi, Cancer Therapeutic Procedure, Colorectal Carcinoma, Immunotherapy, Metastasis from malignant neoplasm of colon and/or rectum, Myers, Opdivo, Pfizer, squibb, Yervoy

Colorectal cancer, metastatic colorectal cancer, Bristol Myers Squibb, Pfizer, Opdivo, Yervoy, Braftovi, ASCO GI 2025, cancer treatment, immunotherapy.

Chinese Vaccine Biotech Ab&B Files for IPO, Drawing Attention from GSK, Merck, and Pfizer

9 months ago talkbio0Tagged Ab&B, Bio-Tech, Biotechnology, Chinese vaccine, Drug Industry, IPO, Pfizer, Pfizer/, SmithKline Beecham

Ab&B Bio-Tech, IPO, Chinese vaccine biotech, GSK, Merck, Pfizer, biotechnology, pharmaceutical industry

Pfizer’s Subcutaneous PD-1 Inhibitor Sasanlimab Achieves Significant Efficacy in High-Risk Non-Muscle Invasive Bladder Cancer

10 months ago talkbio0Tagged BCG Vaccine, BCG-Naïve, Combined Modality Therapy, Event-Free Survival, Inhibitor, Invasive, Non-Muscle, Non-Muscle Invasive Bladder Neoplasms, PDCD1 gene, Pfizer, Sasanlimab, subcutaneous

Pfizer, Sasanlimab, Subcutaneous PD-1 inhibitor, Non-muscle invasive bladder cancer (NMIBC), BCG-naïve, Event-free survival (EFS), Combination therapy with BCG

Pfizer’s Sasanlimab Shows Promising Results in Phase 3 Trial for High-Risk Non-Muscle Invasive Bladder Cancer

10 months ago talkbio0Tagged BCG Vaccine, Blocker, Carcinoma of urinary bladder, invasive, Keytruda, Malignant neoplasm of urinary bladder, Non-Muscle, PDCD1 gene, Pfizer, Phase 3 trial, Sasanlimab

Pfizer, Sasanlimab, PD-1 Blocker, Bladder Cancer, Phase 3 Trial, Non-Muscle Invasive Bladder Cancer, BCG, Keytruda

FDA Mandates Guillain-Barré Syndrome Warning for Pfizer and GSK RSV Vaccines

10 months ago talkbio0Tagged Abrysvo, Arexvy, Cautionary Warning, Guillain-Barré syndrome, Pfizer, Respiratory syncytial virus, SmithKline Beecham, United States Food and Drug Administration, Vaccines

RSV vaccines, Guillain-Barré syndrome, FDA warning, Pfizer, GSK, Abrysvo, Arexvy

Pfizer and PostEra Expand AI-Driven Drug Discovery Partnership to Include Antibody-Drug Conjugates (ADCs)

10 months ago talkbio0Tagged Antibody-Drug, Antibody-Drug Conjugates, Artificial Intelligence, Chemistry, Pharmaceutical, Drug Discovery, Immunostimulating conjugate (antigen), Laboratory, Pfizer, Pfizer/, PostEra, Proton Platform, Small Molecule

AI-driven drug discovery, Antibody-Drug Conjugates (ADCs), Pfizer, PostEra, AI Lab, Proton platform, small molecule therapeutics, medicinal chemistry.